Login to Your Account



Two for two: AAC gives its seal of approval to Enbrel biosimilar

By Mari Serebrov
Regulatory Editor

Wednesday, July 13, 2016

For the second day in a row, the FDA's Arthritis Advisory Committee (AAC) voted unanimously Wednesday to support approval of a biosimilar with extrapolated indications to treat several autoimmune diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription